Synaptonemal complex protein 3 as a novel prognostic marker in early stage non–small cell lung cancer

Abstract

Summary Synaptonemal complex protein 3 (SCP3) is a marker for cell transformation that has prognostic significance in various cancers. However, the prognostic significance of SCP3 has not been studied in non-small cell lung cancer (NSCLC). To investigate the potential correlation between SCP3 and various clinicopathologic parameters, we assessed the expression of SCP3 in archival tumor tissues from 258 NSCLC patients by immunohistochemical staining. By immunofluorescence, SCP3 was detected in both the cytoplasmic and nuclear fractions of NCI-H1299 cell. In tumor samples, SCP3 is detected as cytoplasmic expression pattern and observed in 50 (19.4%) clinical samples by immunohistochemical staining. SCP3 expression was correlated with T status (P=0.008), lymph node metastasis (P=0.010), tumor types (P=0.019) and pleural invasion (P=0.005). In multivariate analysis of patients with early stage disease, increased SCP3 expression predicted worse overall survival in early stage (stage I–II) with pT1 status (P=0.041). These results suggest that positive SCP3 expression is a portent of poor outcome, and may be a potential biomarker in the early stages of the NSCLC for survival and may provide clues in the identification of patients for adjuvant therapy.

Synaptonemal complex protein 3 is associated with lymphangiogenesis in non-small cell lung cancer patients with lymph node metastasis

“…Notably, prior studies demonstrated that continuous IHC score data resulted from digital image analysis may allow identification of IHC cut-off points of prognostic relevance that are either undetected [35] or are less statistically significant [36,37] by manual visual scoring. In the present study, we observed higher SCP3 positivity compared to the previous study [13]. This discrepancy in the findings may be resulted from employed IHC scoring method and lack of well-defined SCP3 cut-off values for positive and negative results.…”

Synaptonemal complex protein 3 is a prognostic marker in cervical cancer

“…Moreover, we observed that SCP3 protein expression was significantly associated with advanced tumor stage (P = 0.002), poor tumor grade (P,0.001), and poor response to chemoradiation therapy (P = 0.005), and exhibited the highest levels of expression in metastatic tissue specimens (Table S1). Notably, consistent with our previous report in non-small cell lung cancer [8], high SCP3 expression in cervical cancer conferred a significantly shorter survival time, suggesting that it may be a potential prognostic predictor for cervical cancer. Based on Cox multivariate analysis, SCP3+, pAKT+, SCP3+/pAKT+, and lymph node metastasis was associated with increased risk of recurrence of cervical cancer.…”

Scp3 expression in relation to the ovarian differentiation in the protogynous hermaphroditic ricefield eel Monopterus albus

“…Although the expression of Scp3 has not been reported in normal tissues other than gonads in other vertebrates, Scp3 has been shown to be expressed in human acute lymphatic leukemias (Niemeyer et al 2003) and human cervical cancer cells (Kang et al 2010). The expression of Scp3 in cells other than germ cells could be associated with genetic instability, such as aneuploidy (Chung et al 2013). In the brain of both male and female ricefield Fish Physiol Biochem eels, however, Scp3 immunostaining was not detected by immunohistochemistry (data not shown).…”